Ascendis (IFC-38257)

  • South Africa
Where the impacts of the investment may be experienced.
Financial Institutions
  • International Finance Corporation (IFC)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Bank Risk Rating
Risk rating varies among banks and may refer only to the particular investment and not to the risk for the project as a whole. Projects marked 'U' have an 'Unknown' risk rating at the time of disclosure.
Voting Date
Aug 18, 2016
The estimate day the bank will vote on a proposed investment. The decision dates may change, so review updated project documents or contact the EWS team.
The holder of the loan, grant, or other investment.
  • Education and Health
The service or industry focus of the investment. A project can have several sectors.
Investment Amount (USD)
$ 30.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Bank Documents
Primary Source

Original disclosure @ IFC website

Updated in EWS Aug 2, 2017

Disclosed by Bank May 24, 2016

Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description
The company is seeking funds to acquire Remedica and Scitec (the “project”). Remedica is a generic pharmaceutical company with well-known brands in Africa, the Middle East, and European Union, and owns a portfolio of over 500 generic pharma products. Remedica’s head office is based in Limassol, Cyprus where it manufactures all its own products, including tablets, capsules, gels and creams, suppositories, oral liquids, powders, and syrups. Remedica operates five separate manufacturing facilities covering 40,000 sqm, all located on the same site encompassing a facility for general products, a Penicillin factory, a Cephalosporin factory, and an anti-cancer and a hormone factory, and offers the potential for Ascendis to transfer this technology into their home market, or expand into Africa. Scitec is engaged in the production and trading of mono- and multicomponent body building, sports nutrition, well-being products, and dietary supplements. The manufacturing facility is based in Hungary, although it has offices throughout Europe.
Investment Description

Contact Information
ACCOUNTABILITY MECHANISM OF IFC The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at You can learn more about the CAO and how to file a complaint at